

Higher Autoantibody Levels and Recognition of a Linear NH₂-terminal Epitope in the Autoantigen GAD₆₅, Distinguish Stiff-Man Syndrome from Insulin-dependent Diabetes Mellitus

By John Kim,* Mark Namchuk,* Teodorica Bugawan,† Qin Fu,* Marc Jaffe,* Yuguang Shi,* Henk-Jan Aanstoot,* Christoph W. Turck,§ Henry Erlich,‡ Vanda Lennon,|| and Steinunn Baekkeskov*

From the *Departments of Medicine and Microbiology/Immunology, Hormone Research Institute, University of California San Francisco, San Francisco California 94143; the †Department of Human Genetics, Roche Molecular Systems, Alameda, California 94501; the §Howard Hughes Medical Institute, and Department of Medicine, University of California San Francisco, San Francisco, California; 94143; and the ||Departments of Neurology, Immunology, and Laboratory Medicine/Pathology, Mayo Clinic Medical School, Rochester, Minnesota 55905

Summary

The smaller form of the GABA-synthesizing enzyme glutamic acid decarboxylase (GAD₆₅) is a major autoantigen in two human diseases that affect its principal sites of expression. Thus, destruction of pancreatic β cells, which results in insulin-dependent diabetes mellitus (IDDM), and impairment of GABA-ergic synaptic transmission in Stiff-Man syndrome (SMS) are both characterized by circulating autoantibodies to GAD₆₅. Anti-GAD₆₅ autoantibodies in IDDM are predominantly directed to conformational epitopes. Here we report the characterization of humoral autoimmune responses to GAD₆₅ in 35 SMS patients, of whom 13 (37%) also had IDDM. All SMS patients immunoprecipitated native GAD₆₅ and the main titers were orders of magnitude higher than in IDDM patients. Furthermore, in contrast to the situation in IDDM, autoantibodies in 35 of 35 (100%) of SMS patients recognized denatured GAD₆₅ on Western blots. Two major patterns of epitope specificity were identified on Western blots. The first pattern, detected in 25 of 35 SMS patients (71%), of whom 11 had IDDM (44%), was predominantly reactive with a linear NH₂-terminal epitope residing in the first eight amino acids of GAD₆₅. Nine of nine individuals who were HLA-haplotyped in this group carried an IDDM susceptibility haplotype and HLA-DR3, DQw2 was particularly abundant. The second pattern, detected in 10 of 35 patients (29%) of whom two had IDDM (20%), included reactivity with the NH₂-terminal epitope plus strong reactivity with one or more additional epitope(s) residing COOH-terminal to amino acid 101. The second epitope pattern may represent epitope spreading in the GAD₆₅ molecule, but may also include some cases of epitope recognition associated with IDDM resistant HLA-haplotypes. The principal NH₂-terminal linear epitope in GAD₆₅ distinguishes the reactivity of SMS and IDDM autoantibodies and may be a determinant of pathogenicity for GABA-ergic neurons. The greater magnitude and distinct specificity of the humoral response to GAD₆₅ in SMS may reflect a biased involvement of the T helper cell type 2 (Th2) subset of CD4⁺ T cells and antibody responses, whereas IDDM is likely mediated by the Th1 subset of CD4⁺ T cells and cytotoxic T cell responses.

The synthesizing enzyme for the inhibitory neurotransmitter GABA, glutamic acid decarboxylase (GAD)¹, is encoded by two nonallelic genes, GAD₆₅ and GAD₆₇ (1), which share a similar exon-intron structure and are probably

derived from a common ancestral gene (2). These two GAD proteins share extensive homology except in their first 95 amino

¹ Abbreviations used in this paper: AET, aminoethylisothiouranium bromide; DTT, dithiothreitol; F/M, female/male; GAD, glutamic acid decarboxylase;

HMAP, Hepes/NaOH/MgCl₂, AET, PLP; ICA, islet cell cytoplasmic antibodies; IDDM, insulin-dependent diabetes mellitus; JDF, Juvenile Diabetes Foundation; PLP, pyridoxal 5'phosphate; PVDF, polyvinylidene difluoride; SMS, Stiff-Man syndrome; TBS, tris-buffered saline.

acids (1). Both are synthesized as hydrophilic soluble molecules (3), but only GAD₆₅, which is found in neurons and pancreatic β cells, undergoes posttranslational lipid modification in the NH₂-terminal domain to become targeted and anchored to the membrane of synaptic-like microvesicles, which store and secrete GABA (3–5).

Autoantibodies to GAD₆₅ are detected in ~80% of individuals who develop insulin-dependent diabetes mellitus (IDDM) (6, 7). Autoantibodies to GAD₆₇ are detected in only a small fraction of IDDM patients, and seem to represent anti-GAD₆₅ autoantibodies that crossreact with the larger isoform (8, 9). T lymphocytes are implicated as the effectors of β cell destruction (10). GAD₆₅ has been identified as the primary T cell autoantigen in the nonobese diabetic mouse model of IDDM, and induction of tolerance to GAD₆₅ in young mice prevents the disease (11, 12).

Autoantibodies to GAD₆₅ are also found in a rare neurological disorder called Stiff-Man syndrome (SMS) (13). Stiffness of axial muscles and superimposed painful spasms are characteristic of this disorder and are alleviated by benzodiazepines, a finding that is consistent with the hypothesis that SMS represents an impairment of GABA-ergic neurotransmission in the central nervous system (14). SMS is characterized by a 30–40% coincidence with IDDM. Conversely, however, SMS is diagnosed in <1/10⁴ IDDM patients and in <1/10⁶ individuals in the general population. If GAD is a primary autoantigen in both SMS and IDDM, the question is why the diseases do not always coincide. At least three possibilities can be suggested. First, neurons and β cells may express forms of GAD that differ antigenically. Second, the accessibility of GAD to the immune system may differ in the two tissues because neurons, but not β cells, are protected by the blood brain barrier. Third, the humoral and/or cellular immune responses to GAD₆₅ may differ in the two diseases. The demonstration that β cell and neuronal forms of GAD are identical with regard to antigenicity and sequence (3, 15–17) seems to exclude the first possibility, although minor differences in posttranslational modification have not been ruled out. The two tissues clearly do differ in their vulnerability to immune system interactions. In addition to their sequestration behind the blood brain barrier, neurons do not express MHC class I antigens (18). In contrast, β cells are readily accessible to circulating immunological effectors and express MHC class I antigens (19) that can target them for killing by cytotoxic T lymphocytes (20, 21). These differences can explain why SMS is a rare disease in individuals afflicted with IDDM, but not why only 30–40% of SMS patients develop diabetes. To explain the low penetrance of IDDM in SMS, we hypothesize that the immune mechanisms in SMS and IDDM reflect distinct recognition of GAD.

To assess possible differences in recognition of GAD, we have begun to characterize the target epitopes of the humoral autoimmune response in the two diseases. The predominant epitopes for GAD₆₅ autoantibodies associated with IDDM are conformational and localized to the COOH-terminal and middle regions of the GAD₆₅ molecule (22). In rare cases where IDDM autoantibodies recognize the denatured GAD₆₅ molecule on Western blots, the epitope has been

localized to the COOH-terminal domain and may represent the phenomenon of restricted epitope spreading (22, 23). We and others have shown that GAD autoantibodies in SMS react with the denatured antigen on Western blots (7, 13, 24) suggesting that the humoral autoimmune response to GAD₆₅ differs in IDDM and SMS. In the present study we have characterized an epitope that clearly distinguishes SMS autoantibodies from those of IDDM.

Materials and Methods

Antisera. Sera were obtained with informed consent from 33 SMS patients identified at the Mayo Clinic (Rochester, MN) during the period of 1989–1992, and from two patients who attended the University of California, San Francisco (UCSF) Neurology Clinic during the period of 1991–1993. The patients were diagnosed using uniform standardized criteria developed at the Mayo Clinic and adapted at UCSF (14). The age, sex, age at onset of SMS, and the coexistence with other autoimmune disorders, including IDDM, are shown in Table 1. Control human sera included: (a) Sera from 11 newly diagnosed IDDM patients. This group included a serum (no. 675, “IDDM serum 2” in this study, female aged 11 years) that is used as a standard for quantitative analyses of GAD₆₅ autoantibodies by several laboratories (9, 25, 26) and has an arbitrary value of 10 in our GAD₆₅ antibody assay (26). The remaining sera in this group were from 10 individuals selected for having the highest GAD₆₅ antibody reactivity amongst 143 newly diagnosed IDDM patients collected from the USA and Scandinavia (Table 2). (b) Sera from 10 healthy controls (female/male [F/M] = 3:7; mean age \pm SD = 29.8 \pm 4.1; range 22–34). (c) Sera from 10 patients diagnosed at UCSF with polyendocrine autoimmune disorder but not SMS (F/M = 9:1; mean age \pm SD = 45.7 \pm 19.5; range 31–75). Each autoimmune disorder coexisting in the SMS patients was represented in at least one of these control patients. Eight of the polyendocrine control patients had IDDM (duration 0–31 yr; mean \pm SD 12.6 \pm 12.1) and six of those were GAD₆₅ antibody positive (Table 2).

Rabbit antisera 1267 and 1701 were raised against a 19-amino acid peptide derived from the COOH terminus of rat GAD₆₇. Both sera react equally well with rat and human GAD₆₅ and GAD₆₇ (3, 27). Rabbit antiserum 2001 was raised against a peptide corresponding to residues 83–93 of human GAD₆₅. The mouse monoclonal antibody GAD6 (28) is specific for GAD₆₅ (3, 27) and was kindly donated by Dr. D. Gottlieb (Washington University, St. Louis, MO). The mouse hybridoma GAD1 (29) was obtained from the American Type Culture Collection (Rockville, MD).

Immunoprecipitation Analyses. GAD₆₅ autoantibodies were analyzed by a quantitative immunoprecipitation assay using [³⁵S]methionine labeled rat GAD₆₅ transiently expressed in COS-7 cells as described in detail elsewhere (26). Human sera were analyzed at dilutions of 1:10, 1:100, 1:1000, 1:10,000, and 1:100,000, and resulting immune complexes were isolated on protein A-Sepharose (Pharmacia LKB, Piscataway, NJ) and analyzed by SDS-PAGE. Seropositivity was scored on the basis of a visible GAD₆₅ signal obtained by analyses using a model 425 Phosphor-Imager (Molecular Dynamics, Inc., Sunnyvale, CA). Thus, each immunoprecipitate was quantitated by phosphorimaging with IDDM serum 2 (no. 675) serving as a positive standard. GAD₆₅ antibody values were calculated using the formula: $10 \times [(value\ for\ the\ GAD_{65}\ immunoprecipitate\ band\ in\ an\ unknown\ serum\ subtracted\ by\ value\ for\ background\ area\ of\ identical\ size)/(value\ for\ IDDM\ serum\ 2\ subtracted\ by\ value\ for\ background\ area\ of\ identical\ size)]$. This

Table 1. *GAD₆₅ Antibodies and ICA in 35 SMS Patients*

SMS Patient No.	Sex	Age at serum sampling	SMS age at onset	IDDM/age at onset	ICA	Other auto-antibodies/ disorders	GAD ₆₅ Ab IMP titer
					<i>JDF units</i>		
1*	F	45	34	no [†]	8,620	yes	5,260
2	F	48	43	no [§]	819	yes	495
3	F	40	36	no [§]	3,940	yes	10,150
4	F	41	39	no	8,620	yes	13,310
5	F	51	48	49	819	yes	2,920
6	F	35	34	34 [§]	8,620	yes	5,440
7	F	34	26	no [§]	1,610	N/A	7,040
8	M	40	27	no	1,800	yes	930
9	M	40	36	no [§]	>10,000	N/A	16,620
10	M	64	56	no [§]	171	N/A	578
11	F	34	29	no	1,800	yes	3,460
12	F	43	40	no	8,620	yes	11,140
13	M	57	<47	no	1,087	yes	1,166
14	F	38	34	33 [§]	554	yes	1,260
15	F	59	50	57	2,660	yes	2,870
16*	F	44	42	no	7,570	yes	3,380
17	F	36	32	16	253	yes	444
18	F	39	37	35	3,940	N/A	2,920
19	F	54	44	no [§]	345	yes	4,100
20*	M	36	35	no	>20,000	N/A	65,700
21	M	63	59	63	1,800	yes	1,654
22	F	65	64	55 [§]	374	yes	1,551
23	F	56	<52	Pre-DM 52	>10,000	yes	10,660
24	M	68	61	Pre-DM 60	Neg.	yes	44
25	F	39	39	No	1,210	yes	3,450
26	M	49	47	Pre-DM 49	115	None	173
27	F	50	N/A	no	3,110	yes	6,090
28	F	40	39	no	2,370	N/A	2,600
29	M	50	47	no	2,370	N/A	1,338
30	F	50	39	39	>10,000	yes	9,720
31	M	70	67	70	5,110	yes	1,561
32*	F	47	43	no	>10,000	yes	20,280
33	F	45	37	no	>10,000	yes	9,500
34*	F	50	46	no	>10,000	N/A	1,561
35	F	60	48	no	5,110	N/A	752

* African Americans, the remaining patients are caucasian.

† Father had NIDDM.

§ IDDM in first degree relative(s). N/A, information not available.

IMP, immunoprecipitation.

Table 2. Summary of GAD₆₅ Antibody Titers in SMS, IDDM, and Polyendocrine Autoimmune Disorder (PE) Patients

	n	Sex F/M	Age mean ± SD	Age range	GAD ₆₅ Ab IMP titer median	GAD ₆₅ Ab IMP titer range
SMS	35	25/10	48 ± 10.1	34–70	2920	44–65,700
IDDM	10*	2/8	4.6 ± 5.0	0.9–15	20.3	14.7–36.6
PE	6†	5/1	48 ± 19	11–75	8.2	1.3–15.9

* Selected for having the highest GAD₆₅ antibody titer amongst 143 newly diagnosed IDDM patients, 115 (80%) of whom were positive for GAD₆₅Ab with a median titer of 1.7.

† From a group of 10 PE patients, 6 of whom were GAD₆₅Ab positive. IMP, immunoprecipitation.

assay was used in the first GAD antibody workshop (Orlando, FL, April 1993) and yielded 100% sensitivity and 100% specificity.

Expression Systems and Protein Synthesis. The generation of recombinant baculoviruses harboring either rat GAD₆₅ (4), human GAD₆₅, or human GAD₆₇ (22) was described earlier. A recombinant baculovirus for expressing an NH₂-terminal deletion mutant of rat GAD₆₅ lacking the first 101 amino acids was generated by first making a 2-kb deletion mutant by oligonucleotide-directed mutagenesis (5), cloning this mutant into the EcoRI site of pBluescript (Stratagene, La Jolla, CA), from which it was released by SmaI and NotI digestions, and finally inserting the mutant cDNA into the SmaI and NotI sites of the baculovirus expression vector pVL1393 (Invitrogen, San Diego, CA). A clone containing the sense orientation for the Δ1-101 mutant of rat GAD₆₅ was used in a calcium phosphate cotransfection with wild-type *Autographa californica* nuclear polyhedrosis virus. Recombinant viruses were isolated as described (30). Recombinant proteins were expressed from the baculovirus constructs in Sf9 cells. Generation of NH₂-terminal deletions of a rat GAD₆₅ mutant in which cysteines at positions 30 and 45 have been substituted with alanines, and insertion of the mutants into the COS-cell expression vector pSV-SPORT (GIBCO BRL, Gaithersburg, MD) were described earlier (5). Deletion mutants lacking the first NH₂-terminal 8 (Δ1-8), 15 (Δ1-15), and 23 (Δ1-23) amino acids of rat GAD₆₅, respectively, were produced by transient transfection of COS-7 cells using lipofectamine (GIBCO BRL).

For Western blot analyses, Sf9 or COS-7 cells expressing GAD₆₅, GAD₆₇, or NH₂-terminal deletion mutants of GAD₆₅ were washed twice in cell harvest buffer (10 mM Hepes/NaOH, pH 7.4, 150 mM NaCl, 10 mM benzamidine/HCl, 0.1 mM PMSF), and lysed in HMAP buffer (10 mM Hepes/NaOH, pH 7.4, 1 mM MgCl₂, 1 mM aminoethylisothiouranium bromide hydrobromide [AET], 0.2 mM pyridoxal 5'phosphate [PLP]) containing 1% Triton X-114, and 0.1 mM PMSF at 4°C. After centrifugation at 264,000 g, 4°C, for 30 min, the supernatant was collected and prepared for SDS-PAGE by boiling for 3 min in SDS sample buffer at a final concentration of 8 mM Tris/HCl, 15% sucrose, 2% SDS, 5% β-mercaptoethanol, and 0.006% bromophenol blue.

A 58-kD tryptic fragment containing the COOH terminus was generated from rat or human GAD₆₅ produced in Sf9 cells. Approximately 60 × 10⁶ Sf9 cells were harvested 72 h after infection with the appropriate baculovirus. The cell pellet was extracted in 4 ml of HMAP buffer supplemented with 1% Triton X-114 and 0.1 mM PMSF for 1 h on ice. The lysate was diluted with 21.6 ml of HEMAP (HMAP supplemented with 1 mM EGTA) and treated with 5.4 ml of *N*-tosyl-L-phenylalanine-chloromethylketone (TPCK)-treated trypsin (2 mg/ml; Sigma Chemical Co., St. Louis,

MO) for 20 min at 0°C. The reaction was quenched by adding 400 μl of 100 mM PMSF and 6.8 ml 5× SDS-sample buffer. This material was used for Western blot analysis.

The approximate location of the tryptic cleavage site was estimated based on the relative molecular weight of the fragment obtained by SDS-PAGE, followed by sequencing of the NH₂ terminus of the isolated peptide. Approximately 300 × 10⁶ Sf9 cells infected for production of human GAD₆₅ were harvested and suspended in HMAP buffer containing 1% Triton X-114 and 0.1 mM PMSF, and incubated for 1 h on ice. The cells were then homogenized using a Tissumizer homogenizer (Tekmar Co., Cincinnati, OH) for 30 s on ice. The cell lysate was centrifuged at 100,000 g and the supernatant was applied to a phenyl-Sepharose CL-4B column (Pharmacia LKB) preequilibrated in buffer A (50 mM potassium phosphate, pH 7.0, 10 mM dithiothreitol [DTT], 1 mM AET, 0.2 mM PLP) containing 2 M ammonium sulfate, then washed with 5 column volumes of buffer A containing 2 M ammonium sulfate. The protein was eluted using buffer A and a gradient with initially 0% Triton X-100 and 1.5 M ammonium sulfate, and finally 2% Triton X-100 and 0 mM ammonium sulfate. Fractions containing GAD activity were pooled and subjected to immunoaffinity chromatography using the GAD1 monoclonal antibody as described (27) except that the gel matrix was washed sequentially with 10 volumes of buffer B (10 mM Hepes/NaOH, pH 7.4, 10 mM DTT, 1 mM AET, 0.2 mM PLP), 10 volumes of buffer B with 0.5 M NaCl and 10 volumes of buffer B before elution of GAD₆₅ in 1-ml aliquots of buffer A at pH 11 and neutralized in 100 μl 1M potassium phosphate pH 6.5, 0.2 mM PLP. Protein concentrations were determined using Coomassie Plus protein reagent (Pierce, Rockford, IL), using BSA as a standard. Purified human GAD₆₅ (81 μg/ml, 100 μl) was treated with 5 μl of 0.2 mg/ml TPCK-treated trypsin (1 μg in 5 μl) for 1 h at 0°C. The reaction was quenched by adding 10 μl of 100 mM PMSF and freezing at -20°C. The sample (13 pmol of the 58-kD protein) was subjected to preparative SDS-PAGE and blotted to Pro Blot polyvinylidene difluoride (PVDF) membrane (Applied Biosystems, Inc., Foster City, CA). A slice of PVDF paper containing the 58 kD fragment was used for gas phase sequencing using a gas phase sequencer (model 470A; Applied Biosystems, Inc.). The phenylthiohydantoin (PTH)-derivatives were identified by reverse-phase HPLC using an on-line PTH analyzer (model 120A; Applied Biosystems, Inc.). Electrophoresis, blotting, and sequencing were carried out at the Biomedical Resource Center, UCSF. The results were consistent with the generation of two fragments by cleavage at either position 69 (lys) or 70 (arg).

Western Blot Analyses. To compare serum IgG specificities for GAD₆₇, GAD₆₅, the 58-kD fragment of GAD₆₅, and deletion mu-

tants of GAD₆₅, it was essential to load equal amounts of each protein on the gel. A preparation of full-length rat or human GAD₆₅ was chosen as an arbitrary standard and titrated on Western blots. Each protein preparation was titrated and calibrated against this standard to obtain an identical signal on Western blots immunostained with rabbit 1267 antiserum, which is equally reactive with both GAD₆₇ and GAD₆₅ (27). Finally, the concentrations of different proteins which consistently gave a signal equivalent to that of the GAD₆₅ standard were tested several times on the same blots, to ensure equivalent signal intensities. Equal amounts of full-length GAD₆₇, GAD₆₅, 58-kD trypsin fragment of GAD₆₅, or deletions mutants of GAD₆₅ were then subjected to SDS-PAGE, blotted to Immobilon PVDF transfer membrane (Millipore Corp., Bedford, MA) and analyzed for binding of human IgG and animal antiserum IgG after dilution of sera as described earlier (27). In some experiments, human sera were preabsorbed using a homogenate of noninfected Sf9 cells as indicated. Sf9 cells were homogenized in HMAP buffer (10⁷ cells/ml) using a Tissumizer homogenizer (Tekmar Co.) for 1 min on ice. The homogenate was centrifuged at 264,000 g. Sera were incubated with 0.2 vol of Sf9 cell supernatant for 16 h at 4°C, diluted, and used for immunostaining of Western blots (27).

Synthesis of Peptides for Blocking Studies. Peptides of 20 residues, spanning amino acids 1–119 of the human GAD₆₅ molecule (17), and each overlapping the next sequence by 9 amino acids, were synthesized by a multiple peptide synthesizer (Advanced Chemtech, Louisville, KY), using fluorenylmethoxycarbonyl (FMOC)-protected amino acids and amino acid resins (Bachem California, Torrance, CA). Side chain deprotection and cleavage from the resin were performed with trifluoroacetic acid/anisole/dimethylsulfide (9:0.5:0.5 vol/vol), and the peptides were extracted with ether. Peptide identity was confirmed by protein sequence analysis with a Protein Sequencer (Applied Biosystems, Inc.). For blocking studies, the peptides were solubilized in TBS/Tween-20 buffer (20 mM Tris/HCl, pH 7.4, 150 mM NaCl, and 0.1% Tween-20) to a concentration of 0.5 mg/ml. All peptides, except no. 8, dissolved readily in this buffer. Because peptide 8 (residues 78–97) was only partially soluble, it was used as a saturated solution which effectively blocked the binding of rabbit antiserum 2001 (reactive with residues 83–93 in human GAD₆₅).

Dot Blot Analyses. Human GAD₆₅ was extracted from Sf9 cells and isolated to ≥95% purity by immunoaffinity chromatography as described previously (27). Purified GAD₆₅ at a concentration of 55 μg/ml in 100 mM potassium phosphate, 0.2 mM PLP, 1 mM AET, 0.1% SDS, was boiled for 3 min before spotting (0.2 μg) on Immobilon PVDF transfer membrane (Millipore Corp.) using a BRL HybridDot Manifold (GIBCO BRL). The PVDF membrane was blocked with TBS/Tween-20 buffer containing 3% milk protein for 1 h at room temperature. The membranes were incubated with sera (diluted in TBS/Tween-20 buffer containing 2% BSA) for 1.5 h at room temperature; after three washes of 5 min in TBS/Tween-20, they were incubated with alkaline phosphatase-conjugated goat anti-human IgG (Zymed Laboratories, Inc., South San Francisco, CA) or anti-rabbit IgG (Zymed Laboratories, Inc.) at a dilution of 1:500 in 3% milk/TBS/Tween-20 buffer for 1 h at room temperature. After two washes of 5 min in TBS/Tween-20 and one in TBS buffer, the blots were developed by incubation for 3 min in 0.4 mM 5-bromo-4-chloro-3-indolyl phosphate and 0.4 mM nitro blue tetrazolium in 150 mM Tris-HCl, pH 9.5, 100 mM NaCl, and 5 mM MgCl₂.

Human sera (SMS, IDDM, polyendocrine, and normal sera) were diluted 1:100, 1:200, and 1:500 in TBS/Tween-20 buffer, 2% BSA. Rabbit antisera 1701 and 2001 were diluted in the same buffer,

1:200,000 and 1:2,000, respectively. For peptide blocking experiments, diluted sera were incubated overnight at 4°C with either a mixture of peptides (0.3 μg/μl each), an individual peptide (0.3 μg/μl), human GAD₆₅ (5.5 μg/ml), or no additive, before incubation with dot blots of purified human GAD₆₅.

Analyses of Islet Cell Cytoplasmic Antibodies (ICA). ICAs were analyzed by indirect immunofluorescence using frozen sections of human pancreas from blood group O-positive donors of cadaveric kidneys (31). Serum samples were titrated and end point titers were defined as the highest dilution of detectable ICA-staining. Positive samples were expressed in Juvenile Diabetes Foundation (JDF) units by comparing their end point dilution to a standard calibration curve using the international JDF reference serum provided by the Immunology of Diabetes Workshops. This assay has performed in category A in the ICA proficiency program conducted under the auspices of the Immunology of Diabetes Workshops (32).

HLA-typing. DRB1, DQB1, and DQA1 typing was performed with a PCR dot blot technique as described (33, 34).


Results

SMS Sera Contain Higher Levels of Immunoprecipitating GAD₆₅ Autoantibodies than IDDM Sera. Sera from 35 SMS patients were analyzed for GAD₆₅ autoantibodies by immunoprecipitation of [³⁵S]methionine-labeled Triton X-114 detergent phase extracts of COS-7 cells expressing rat GAD₆₅ (Table 1). Anti-GAD₆₅ IgG titers, quantified in serially diluted sera by phosphorimager analyses, were orders of magnitude higher in SMS sera (Tables 1 and 2) than in IDDM sera and sera from patients with polyendocrine autoimmune disorder (Table 2). Thus, the GAD₆₅ binding capacity of SMS IgG is orders of magnitude higher than that of IDDM IgG. Titers of ICA in the SMS patients were also higher (Table 1, median titer 2660 JDF units) than in 327 ICA-positive newly onset IDDM sera analyzed by the same assay (median titer 110 JDF units) (31). The correlation coefficient between ICA and GAD₆₅ autoantibody titers in the 35 SMS patients was 0.77.


SMS Epitopes Recognized in Denatured GAD₆₅, Are Absent in GAD₆₇, and Distinct from IDDM Epitopes. The 35 SMS sera were analyzed by immunoblotting for reactivity with equal amounts of denatured GAD₆₅ and GAD₆₇. Additional sera were tested from 11 IDDM patients, 10 healthy individuals, and 10 patients with polyendocrine autoimmune disorder without SMS. No serum IgG bound to human or rat GAD₆₇ on Western blots (Fig. 1 A, lanes 3, 5, 7, 9, 11). IgG in all SMS sera reacted specifically with GAD₆₅ (Fig. 1 A, lanes 4, 6, 8), but no reactivity was found in the sera from patients with IDDM (Fig. 2, lanes 22 and 25), polyendocrine autoimmunity (Fig. 1, lane 10), or healthy control subjects (Fig. 1, lane 12; Fig. 2, lanes 28 and 31) at the same dilution. To analyze whether the lack of reactivity of IDDM sera with GAD₆₅ on Western blots was due to low titers rather than differences in epitope recognition, the IDDM sera used in this study were also analyzed at lower dilutions to obtain a final GAD₆₅ antibody titer of 4 and compared with SMS sera analyzed at the same titer. To avoid nonspecific binding of Sf9 cell proteins at high IgG concentrations, the sera were preabsorbed with noninfected Sf9 cell lysates. At

the low dilutions, IDDM sera still failed to react with denatured GAD₆₅ on Western blots (Fig. 1 B). The results demonstrate that SMS autoantibodies are directed at epitope(s) in the GAD₆₅ molecule that are resistant to denaturation by SDS and are therefore likely to be continuous. Reactivity with these GAD₆₅-specific epitope(s) qualitatively distinguishes SMS autoantibodies from anti-GAD₆₅ autoantibodies found in IDDM and polyendocrine autoimmune disorder in the absence of SMS.

SMS Autoantibodies Recognize Epitopes in the NH₂-terminal Region of Denatured GAD₆₅. Since GAD₆₅ differs most significantly from GAD₆₇ in the first 95 amino acids, we speculated that this region might harbor GAD₆₅-specific SMS epitopes recognized by immunoblotting. To address this possibility, all sera were analyzed in parallel for reactivity with equal amounts of full-length rat GAD₆₅, a 58-kD tryptic fragment of rat GAD₆₅ lacking the first 69 or 70 amino acids, and a 55-kD deletion mutant lacking the first 101 amino



A



B

Figure 1. SMS sera recognize GAD₆₅ but not GAD₆₇ on Western blots and this reactivity distinguishes SMS from IDDM and polyendocrine autoimmunity in the absence of SMS. (A) Lysates of Sf9 cells expressing human GAD₆₇ (lanes 1, 3, 5, 7, 9, 11) or GAD₆₅ (lanes 2, 4, 6, 8, 10, 12) produced from a baculovirus expression system were subjected to SDS-PAGE, blotted to a PVDF membrane, and immunostained using the human sera indicated (PE, polyendocrine patient serum; NHS, normal human serum) at dilutions of 1:500 and the rabbit anti-GAD antiserum 1267 at dilution 1:100,000. (B) Lysates of Sf9 cells expressing human GAD₆₇ (lanes 1, 3, 5) or GAD₆₅ (lanes 2, 4, 6) immunostained with SMS and IDDM sera preabsorbed to a Sf9-cell lysate and diluted (SMS22, final dilution 1:388; IDDM1, final dilution 1:9) to obtain a titer of approximately 4 for GAD₆₅ antibodies. Immunostaining with the 1267 antiserum (dilution 1:20,000) is shown in lanes 1 and 2.

Table 3. Distribution of SMS-Patients According to Patterns of Epitope Recognition in Denatured GAD₆₅

Pattern	Recognition of epitopes			SMS-patients no.
	Linear NH ₂ -terminal epitope	NH ₂ -terminal epitope predominant	Epitope in a Δ101 mutant	
IA	yes	yes	no	1,2,5,8,17,22,27,28,31
IB	yes	yes	weak	7,10,11,13,14,15,16,19,21,23,24,25,26,29,30,35
II	yes	no	strong	3,4,6,9,12,18,20,32,33,34

acids of rat GAD₆₅ (GAD₆₅Δ1-101) (Fig. 2 and Table 3). Among the SMS sera, two major patterns of reactivity were observed. The majority (25 of 35, or 71%) of SMS sera exhibited pattern I, in which reactivity with full-length GAD₆₅ was much stronger than with both the 58- and 55-kD fragments. This serological pattern suggests that the NH₂-terminal 69 or 70 amino acids in rat GAD₆₅ harbor a major linear epitope(s) (Fig. 2, lanes 4–15, and Table 3). Among the pattern I sera, IgG in 9 (pattern IA) reacted strongly with the full-length GAD₆₅ protein, but did not recognize the 58- and 55-kD fragments, demonstrating that the recognition of denatured rat GAD₆₅ was limited to the first 69 or 70 amino acids (Fig. 2, lanes 4–9). IgG in the remaining 16 SMS sera of the pattern I group (pattern IB) reacted strongly with the full-length protein, and were significantly less reactive with the 58- and 55-kD fragments. This result again suggested IgG that recognized a major epitope in the first 69 or 70 amino acids but, in addition, minor epitope(s) further downstream in GAD₆₅ (Fig. 2, lanes 10–15, and Table 3). Thus for 71% of the SMS sera (pattern IA and B), the major epitope recognized in denatured rat GAD₆₅ resides in the first 69 or 70 amino acids. Pattern II reactivity, found in 10 of 35 SMS sera (29%, pattern II), was distinctly different in that reactivity with both the 58-kD tryptic fragment and the 55-kD deletion mutant was only minimally less than reactivity with the full-length protein (Fig. 2, lanes 16–21, and Table 3). Thus 29% of the SMS patients had autoantibodies that recognized an additional major epitope(s) further downstream in the denatured GAD₆₅ molecule. In sum, residues 1–69 or 1–70 in rat GAD₆₅ contribute to a linear epitope(s) that is recognized by IgG in serum of all SMS patients, and residues COOH terminal to amino acid 101 in rat GAD₆₅ contribute to a second antigenic region that is recognized by IgG in only some SMS patients.




Figure 2. SMS sera show two patterns of reactivity with 58- and 55-kD COOH-terminal fragments of rat GAD₆₅. Full-length GAD₆₅, a 58-kD tryptic fragment of rat GAD₆₅, and a 55-kD NH₂-terminal deletion mutant of rat GAD₆₅ lacking amino acids 1–101, were subjected to SDS-PAGE, blotted to PVDF membrane, and immunostained using the sera at the following dilutions: SMS 1, 12, 18, 30 at 1:500, SMS 2, 21 at 1:200, and IDDM and NHS at 1:500. SMS sera 1, 2, 21, and 30 (pattern I) recognize a major epitope NH₂-terminal to amino acid 69/70, whereas SMS sera 12 and 18 (pattern II) also recognize a strong epitope COOH-terminal to amino acid 101. Among pattern I sera, two subpatterns are observed. In pattern IA, the sera only recognize the full-length protein. In pattern IB, the sera recognize a weaker epitope COOH-terminal to amino acid 101.




Figure 3. An NH₂-terminal peptide of GAD₆₅ specifically blocks the binding of SMS sera. Human GAD₆₅ purified from a baculovirus expression system was spotted on a PVDF membrane and incubated with SMS sera (all at 1:500 dilution) or serum 1701 (raised to peptide 170, corresponding to 19 COOH-terminal amino acids in GAD, at a dilution of

The Principal NH₂-terminal Epitope Resides in the First Eight Amino Acids. To further localize the SMS epitope(s) in the NH₂-terminal region, we synthesized ten peptides, each 20 amino acids long, spanning residues 1–119 in the GAD₆₅ molecule and overlapping each other by 9 amino acids. We tested the ability of the peptides to block the dot blot reactivity of SMS IgG with denatured GAD₆₅. The first series of experiments tested three mixtures of peptides, peptides 1–3 (spanning residues 1–42), peptides 3–6 (residues 34–75), and peptides 7–10 (residues 67–119). The mixture of peptides 1–3 completely blocked the reactivity of pattern IA sera, significantly blocked pattern IB reactivity, and partially blocked pattern II reactivity. These results are consistent with recognition of an epitope in the first 42 amino acids by both pattern I and pattern II sera. The mixture of peptides 4–6 did not affect the binding of SMS IgG to denatured GAD₆₅ (not shown). The mixture of peptides 7–10 partially blocked the reactivities of both pattern I and pattern II sera. We next analyzed the ability of individual peptides 1, 2, 3, 7, 8, 9, and 10 to block the binding of SMS IgG to denatured GAD₆₅. These experiments revealed that only peptide 1 of the 1–3 mixture inhibited the binding of SMS IgG to human GAD₆₅ (see Fig. 3), suggesting that the first 11 residues of the NH₂ terminus of GAD₆₅ contribute to an SMS epitope. This blocking was specific, because peptide 1 did not block

1:200,000) that had been incubated overnight with or without the indicated peptides or human GAD₆₅. Peptide 1 completely blocks the reactivity of serum 1 (pattern IA), significantly inhibits the reactivity of serum 11 (pattern IB), partially inhibits the reactivity of serum 12 (pattern II), but fails to inhibit serum 1701. Peptide 2 does not inhibit binding of any of the sera and peptide 170 only inhibits binding of the serum 1701, which was raised against it.




Figure 4. SMS sera recognize an epitope located in the first eight NH₂-terminal amino acids. Full-length rat GAD₆₅ and short deletion mutants lacking 8 and 15 amino acids, respectively, were subjected to SDS-PAGE, blotted to PVDF membranes, and immunostained with SMS sera at the following dilutions: SMS 1, 7, 9, 12, 30 at 1:500 and SMS 22 at 1:120. All the sera show identical signal or lack of signal with the 1-8 and 1-15 deletion mutants suggesting that they react equally well with both mutants and that the NH₂-terminal epitope resides in the first eight residues, whereas residues 9-15 do not contribute to the epitope.

the binding of rabbit IgG raised against either a COOH-terminal peptide (serum 1701, Fig. 3, panels 25/26) or a peptide encompassing residues 83-93 in the NH₂-terminal region (serum 2001, not shown). Each of these antisera were blocked by the peptide against which they were raised (Fig. 3, panels 31/32 and results not shown). Only peptide 7, in the mixture 7-10, caused any block of the reactivity of SMS sera. However, blocking by peptide 7 was not specific because it also inhibited the reactivity of several rabbit antisera raised against irrelevant peptides (not shown). The reason for nonspecific inhibition by peptide 7 of IgG binding to GAD₆₅ on dot blots is unclear. This activity was not found with peptides 6 and 8, which together account for all but two of the amino acids in peptide 7. Thus, among the NH₂-terminal peptides spanning the first 119 amino acids, only peptide 1 specifically blocked the pattern I reactivity of SMS IgGs and partly inhibited the reactivity of pattern II SMS IgGs. This result is consistent with a major linear NH₂-terminal SMS epitope residing in the first 11 amino acids of GAD₆₅.

To further analyze the reactivity of SMS IgG with the NH₂-terminal region of GAD₆₅, deletion mutants lacking the first 8 and 15 amino acids of rat GAD₆₅, respectively, were analyzed by immunoblotting for interaction with SMS IgG (Fig. 4). These experiments demonstrated that pattern I sera reacted either very weakly (pattern IB) or not at all (pattern IA) with both the Δ1-8 and Δ1-15 deletion mutants (Fig. 4, lanes 4-15). In contrast, pattern II sera recognized both deletion mutants (Fig. 4, lanes 16-21). All of the SMS sera either failed to react with both of the short deletion mutants or showed equal reactivity to both of them (Fig. 4), indicating that the NH₂-terminal linear epitope recognized by SMS sera resides in amino acids 1-8 and that amino acids 9-15 do not contribute to this or other SMS epitopes.

The results of the peptide blocking experiments and analyses of deletion mutants localize the NH₂-terminal epitope recognized by SMS sera to the first 8 amino acids.

HLA-DRB1*0301, DQB1*0201 Is the Predominant Haplotype among Patients of Pattern I Seropositivity. Many autoimmune diseases, including IDDM, are strongly associated with certain MHC class II haplotypes. Thus ≥95% of IDDM patients carry the HLA-DRB1*0301, DQB1*0201 (DR3, DQw2) and/or DRB1*0401, DQB1*0302 (DR4, DQ8) sus-

ceptibility haplotypes (35). To assess whether SMS and IDDM have similar HLA-association, we obtained lymphocytes from 12 of the SMS patients, 9 with serological pattern I and 3 with serological pattern II. (Table 4, and Lennon, V., S. Baekkeskov, T. Bugawan, and H. Erlich, manuscript in preparation). 9 of the 12 SMS patients carried the IDDM associated allele DQw2 (DQB1*0201), 8 on the DR3 (DRB1*0301) and one on the DR7 (DRB1*0701) haplotype. Amongst the DQw2 positive patients, 8 (4 of whom were homozygous) had serological pattern I reactivity and one had pattern II reactivity. The only non-DQw2 positive patient with pattern I was positive for the IDDM associated haplotype DR4, DQ8 (Table 4). Thus all nine patients with serological pattern I but only one of the three patients of pattern II carried an IDDM associated haplotype (Table 4). One of the pattern II patients carried the DRB1*1501, DQB1*0603 (DR2, DQw6) haplotype, which is protective for IDDM (36). The DR3, DQw2 IDDM-associated haplotype is particularly abundant, whereas the DR4, DQw8 IDDM-associated haplotype is rare in the pattern I SMS patients (Lennon V., S. Baekkeskov, T. Bugawan, and H. Erlich, manuscript in preparation).

Table 4. DR and DQ Haplotypes of SMS Patients

SMS patient no.	DRB1		DQB1	GAD ₆₅ Ab Western blot pattern
	DRB1	DQB1		
1	0701, 1302	0201, 0604		I
2	0301, 0301	0201, 0201		I
3	1601, 1401	0502, 0503		II
4	1501, 1301	0603, 0602/03		II
6	0301, 0901	0201, 0303		II
7	0301, 0401	0201, 0301/02		I
8	0404, 1103	0302, 0301		I
11	0301, 0301	0201, 0201		I
14	0301, 0401	0201, 0302		I
15	0301, 0400	0201, 0301		I
19	0301, 0301	0201, 0201		I
30	0301, 0301	0201, 0201		I




Figure 5. Schematic drawing of the GAD₆₅ molecule showing location of humoral epitope areas, membrane anchoring regions, and proteolytic hot spot.

Discussion

Linear Epitopes in GAD₆₅. We have identified a linear NH₂-terminal epitope in the autoantigen glutamic acid decarboxylase, GAD₆₅, that is specifically recognized by autoantibodies in serum of patients with SMS (Fig. 5). This epitope is not recognized by anti-GAD₆₅ autoantibodies that are associated with β cell destruction and development of insulin-dependent diabetes in the absence of SMS (Fig. 5). Hence specificity for the linear NH₂-terminal epitope distinguishes IgG autoantibodies of SMS patients from those of IDDM patients. Antibodies of this specificity may be important for the prediction and diagnosis of SMS.

A recent Western blot study of SMS antibody reactivity with GAD₆₅ used bacterially expressed recombinant fragments of rat GAD₆₅ coupled to a maltose binding protein (24). A fragment containing residues 475–585 of rat GAD₆₅ was recognized much more strongly than full-length GAD₆₅, but the reactivity was abolished by deleting either residues 475–483 or residues 582–585. Based on these results, the authors concluded that the major SMS epitope recognized on Western blots is not linear but rather conformational and generated by refolding of the denatured amino acid 475–585 fragment on nitrocellulose. To explain why a partial fragment was more reactive than wild-type rat GAD₆₅, the authors suggested that the conformational epitope in residues 475–585 is partly cryptic in the native molecule (24). Consistent with our results, Butler et al. (24), also reported that SMS antibodies recognize rat GAD₆₅ fragments containing amino acids 1–95 or 1–195 on Western blots, albeit more weakly than the 475–585 fragment.

The pattern II specificity defined in our study clearly identifies a major epitope(s) COOH-terminal to residue 101 in denatured rat GAD₆₅ on Western blots, which may represent the nonlinear epitope described by Butler et al. (24). However pattern II reactivity only accounted for 29% of the SMS sera analyzed in our study. The remaining 71% of SMS sera had a reactivity that was consistent with recognition of a dominant NH₂-terminal linear epitope but not a major epitope further downstream in denatured rat GAD₆₅ on

Western blots. The difference between our results and those of Butler et al. (24) is not readily explained. Several possibilities can be suggested. First, we have analyzed all SMS patients at the Mayo Clinic and UCSF over the last 5 yr. The study by Butler et al. (24) used sera from 30 patients which were selected from a cohort of 72 SMS patients by unknown criteria; the selection procedure may have favored pattern II sera. Second, their immunoblotting protocol may enhance renaturation of the amino acid 475–585 epitope on Western blots. A third possibility is that the coupling of the 475–585 fragment to a maltose binding protein enhances its refolding on nitrocellulose.

In addition to linear epitopes associated with SMS and IDDM respectively (Fig. 5), Ujihara et al. (36) have identified a third linear epitope in residues 421–442 in the GAD₆₅ protein. This epitope is recognized by IgG in a rare group of IDDM relatives that develop high titers of GAD₆₅ autoantibodies yet carry the HLA-DRB1*1501, DQB1*0603 (DR2, DQw6) haplotype which is protective for diabetes. Interestingly, one of the three SMS patients of pattern II who was HLA-haplotyped carried this haplotype. We speculate that additional pattern II patients, amongst whom IDDM was rare (20%) compared with pattern I patients (44%), may carry alleles that are protective for IDDM and that pattern II may in some cases include recognition of the epitope described by Ujihara et al. (36). In comparison, none of the 9 pattern I patients who were HLA-haplotyped were DR2, DQw6 positive. Rather they all carried one or two IDDM susceptibility alleles and the DR3, DQw2 allele was particularly abundant (7/9).

The NH₂-terminal linear epitope identified in our study is identical in rat and human GAD₆₅, which overall share $\geq 95\%$ sequence homology (17). Although it has been reported that SMS sera recognize rat and human GAD₆₅ equally well (24), our preliminary results suggest that the downstream epitope(s) may differ between the rat and human autoantigen. Thus a 58-kD tryptic fragment of the human protein is recognized more strongly on Western blots by some pattern IB and pattern II sera than its rat counterpart. Generation of mutants of the human protein and expression in cellular expression systems will be important for characterizing the SMS epitope(s) contained in the 58-kD tryptic fragment.

SMS Sera Have an Increased GAD Epitope Recognition Compared with IDDM Sera. Anti-GAD₆₅ autoantibodies differ significantly in SMS and IDDM patients with regard to titers measured by immunoprecipitation. Titers of autoantibodies associated with SMS are orders of magnitude higher than in IDDM sera. Thus SMS is characterized by a much stronger humoral autoimmune response to GAD₆₅ than is IDDM.

Is the strong antibody response to GAD₆₅ in SMS a result of (a) an increased humoral epitope repertoire in this disease compared with IDDM; (b) an enhanced immune response to certain epitopes, or (c) a combination of both? Since no monoclonal autoantibodies are yet available from SMS patients, this question is difficult to address directly. However, considerable indirect evidence suggests that the humoral response in SMS sera is more broad than in IDDM. By immunoprecipitation assay, both SMS and IDDM sera recognize

an NH₂-terminal deletion mutant of GAD₆₅ lacking the first 244 amino acids (22, and Shi, Y., and S. Baekkeskov, unpublished results). This suggests that IgGs in SMS and IDDM sera recognize conformational epitopes in the COOH-terminal half of the molecule. In addition, SMS autoantibodies specifically recognize the linear NH₂-terminal epitope identified in this study. Finally, the incidence of GAD₆₇ autoantibodies in IDDM patients is only 10–20% (8, 9), whereas sera of SMS patients generally immunoprecipitate native GAD₆₇ (24, 37) albeit less efficiently than GAD₆₅ (24). On Western blots, SMS sera react specifically with GAD₆₅ and do not recognize GAD₆₇. In sum, the humoral autoimmune response in SMS seems to include conformational epitopes (detected by immunoprecipitation) as well as linear epitope(s) (recognized in Western blots) that are not recognized by IDDM sera. It is likely that the stronger antibody responses associated with SMS reflect both a broader repertoire of epitopes than is characteristic of IDDM as well as higher affinity for shared epitopes.

The Linear NH₂-terminal Epitope Is Upstream from the Membrane Anchoring Domain and a Proteolytic Hot Spot. We have localized the vesicle targeting and membrane anchoring sequences in GAD₆₅ to the second exon of the molecule (5) that spans amino acids 25–41 (2). GAD₆₅ has a proteolytic hot spot around residues 69–75 encoded by the third exon (Fig. 5). GAD₆₅ can be released spontaneously from islet cell membranes as a 57–58 kD hydrophilic soluble fragment in a time-dependent manner (4). The kinetics of this reaction are consistent with an enzymatic cleavage in islet cells (4). We speculate that this enzymatic activity may also reside in neurons and perhaps result in enhanced exposure of the NH₂-terminal SMS epitope in a 7–8-kD fragment that remains membrane associated after cleavage.

All SMS Patients Are Positive for Antibodies to GAD₆₅. In a study of 32 SMS patients from seven different countries, which only found GAD autoantibodies in 20 patients (63%), it was suggested that SMS patients can be divided into two groups based on whether they have GAD autoantibodies or not (13). Most of the patients analyzed in our study were diagnosed at the Mayo Clinic in Rochester, where the disease was discovered and first described by Moersch and Woltman (38). Two patients were diagnosed at UCSF using clinical diagnostic criteria similar to those of the Mayo Clinic (14). All 35 patients were positive for GAD₆₅ autoantibodies both in immunoprecipitation and Western blot assays. Our results suggest that a diagnosis of SMS using standardized clinical criteria identifies a uniform group of patients with strong humoral autoimmunity to GAD₆₅. A SMS-like disorder associated with breast carcinoma was, however, recently described in four patients who were seronegative for anti-GAD₆₅ antibodies but positive for autoantibodies to a second synaptic vesicle protein, amphiphysin (39). Thus anti-GAD₆₅ autoantibodies may only be a universal characteristic of SMS in the absence of a paraneoplasia.

Role of B Cells and GAD₆₅ Autoantibodies in IDDM and SMS. In spontaneous rodent models of IDDM, disease can

be transferred by T cells but not B cells (10) and immunoelectronmicroscopic studies suggest that β cell destruction is mediated by cytotoxic T cells (40). The primary Th responses to GAD₆₅ in the nonobese diabetic mouse are of the Th1 subset (12), which is consistent with induction of cytotoxic T cell responses. Although autoantibodies to GAD₆₅ have not been implicated as effectors of β cell destruction, it is conceivable that B cells, expressing GAD₆₅-specific IgG on the surface, play an important role in antigen presentation in IDDM. Activated B cells are particularly efficient presenters of low abundance antigens by virtue of antigen capture by their surface immunoglobulins (41) and may well be the principal antigen presenting cells that can maintain chronic autoimmunity to a rare antigen like GAD₆₅ over the several years of progressive β cell destruction. The antibody binding to an antigen can influence its processing in endosomal compartments, and consequently the presentation of epitopes to T cells. Thus, antibody binding can suppress some epitopes while boosting others (42). The identification of humoral autoimmune epitopes in the GAD₆₅ molecule which are associated with either IDDM susceptibility (22) or protection (36) may provide an example of how specificity of autoantibodies can influence autoimmune T cell responses resulting in either β cell destruction and disease, or absence of disease.

Do autoantibodies to GAD₆₅ have a pathogenic role in SMS? Although the strong humoral autoimmune GAD₆₅ responses in SMS may suggest a more direct role of autoantibodies in impairment of GABA-ergic neurons than in destruction of β cells, the pathogenicity of SMS antibodies remains to be shown. It is noteworthy that in the absence of MHC class I expression (18) autoimmune effector mechanisms directed at neurons would be limited to antibody responses. Furthermore, an involvement of a Th2 subset of CD4⁺ cells and strong antibody responses to GAD₆₅ in the pathogenicity of SMS, in contrast to a requirement for a Th1 subset and cytotoxic T cell responses for β cell destruction, is consistent with the dichotomy of the two diseases. Thus SMS without IDDM would ensue in the absence of Th1 helper cell and cytotoxic T cell responses to GAD₆₅.

An autoantibody-mediated impairment of GABA-ergic neurons would, however, require antigen exposure at the cell surface. Although there is some evidence to suggest that GAD can appear on the surface of neurons (43), the mechanisms of such exposure are unclear. GAD₆₅ is believed to anchor at the cytosolic face of synaptic vesicle membranes and surface expression during exocytosis of GABA would require a membrane translocation step. The identification of amphiphysin as a target of autoantibodies in a paraneoplastic SMS-like syndrome (39) does suggest that a localization of a protein to the cytosolic face of synaptic vesicle membranes can predispose it for autoantigenicity and that such proteins may reach the cell surface by an as yet unknown mechanism. Alternatively, SMS autoantibodies may not be involved in pathogenicity but rather be only a marker of disease.

We are grateful to Dr. K. M. McEvoy and colleagues in the Mayo Clinic's Movement Disorder Clinic for their cooperation in identifying SMS patients; Dr. R. Layzer (Department of Neurology) and K. Fye (Department of Medicine) from the University of California, San Francisco, for providing SMS patient material and for valuable discussions; and Dr. A. Tobin (University of California, Los Angeles) and Dr. D. Gottlieb (Washington University, St. Louis, MO) for donation of research materials.

This study was supported by grants from the National Institutes of Health (NIH) (DK-41822-01 and CA-37343). M. Jaffe was supported by a NIH training grant in endocrinology; Y. Shi was supported by a Juvenile Diabetes Foundation fellowship; and H. J. Aanstoot by the Ter Meulen Foundation and by an Albert Renold Fellowship of the European Association for Study of Diabetes.

Address correspondence to Dr. Steinunn Baekkeskov, Hormone Research Institute, 513 Parnassus Ave., Rm. HSW 1090, University of California San Francisco, San Francisco, CA 94143-0543.

Received for publication 3 February 1994 and in revised form 6 May 1994.

References

1. Erlander, M.G., N. J. Tillakaratne, S. Feldblum, N. Patel, and A.J. Tobin. 1991. Two genes encode distinct glutamate decarboxylases. *Neuron*. 7:91.
2. Bu, D.F., and A.J. Tobin. 1994. The exon-intron organization of the genes encoding two human glutamate decarboxylases (GAD₆₅ and GAD₆₇) suggests that they derive from a common ancestral GAD. *Genetics*. In press.
3. Christgau, S., H. Schierbeck, H.-J. Aanstoot, L. Aagaard, K. Begley, H. Kofod, K. Hejnaes, and S. Baekkeskov. 1991. Pancreatic beta cells express two autoantigenic forms of glutamic acid decarboxylase, a 65-kDa hydrophilic form and a 64-kDa amphiphilic form which can be both membrane-bound and soluble. *J. Biol. Chem.* 266:21257.
4. Christgau, S., H.-J. Aanstoot, H. Schierbeck, K. Begley, S. Tullin, K. Hejnaes, and S. Baekkeskov. 1992. Membrane anchoring of the autoantigen GAD₆₅ to microvesicles in pancreatic β -cells by palmitoylation in the NH₂-terminal domain. *J. Cell Biol.* 118:309.
5. Shi, Y., B. Veit, and S. Baekkeskov. 1994. Amino acid residues 24–31 but not palmitoylation of cysteines 30 and 45 are required for membrane anchoring of glutamic acid decarboxylase, GAD₆₅. *J. Cell Biol.* 124:927.
6. Baekkeskov, S., M. Landin, J.K. Kristensen, S. Srikanta, G.J. Bruining, T. Mandrup-Poulsen, C. de Beaufort, J.S. Soeldner, G. Eisenbarth, F. Lindgren, G. Sundquist, and Å. Lernmark. 1987. Antibodies to a 64,000 M_r human islet cell antigen precede the clinical onset of insulin-dependent diabetes. *J. Clin. Invest.* 79:926.
7. Baekkeskov, S., H.-J. Aanstoot, S. Christgau, A. Reetz, M. Solimena, M. Cascalho, F. Folli, and H. Richter-Olesen. 1990. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. *Nature (Lond.)*. 347:151.
8. Velloso, L.A., O. Kämpe, A. Hallberg, L. Christmansson, C. Betscholtz, and F.A. Karlsson. 1993. Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in type 1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. *J. Clin. Invest.* 91:2084.
9. Hagopian, W.A., B. Michelsen, A.E. Karlsen, F. Larsen, A. Moody, C.E. Grubin, R. Rowe, J. Petersen, R. McEvoy, and Å. Lernmark. 1993. Autoantibodies in IDDM primarily recognize the 65,000-M_r rather than the 67,000-M_r isoform of glutamic acid decarboxylase. *Diabetes*. 42:631.
10. Cooke, A. 1990. An overview on possible mechanisms of destruction of the insulin-producing beta cell. *Curr. Top. Micro. Immunol.* 164:125.
11. Tisch, R., X.-D. Yang, S.M. Singer, R.S. Liblau, L. Fugger, and H.O. McDevitt. 1993. Immune response to glutamic acid decarboxylase correlates with insulinitis in non-obese diabetic mice. *Nature (Lond.)*. 366:72.
12. Kaufman, D.L., M. Clare-Salzler, J. Tian, T. Forsthuber, G.S.P. Ting, P. Robinson, M.A. Atkinson, E.E. Sercarz, A.J. Tobin, and P.V. Lehmann. 1993. Spontaneous loss of T cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. *Nature (Lond.)*. 366:69.
13. Solimena, M., F. Folli, R. Aparisi, G. Pozza, and P. De Camilli. 1990. Autoantibodies to GABA-ergic neurons and pancreatic β cells in stiff-man syndrome. *N. Engl. J. Med.* 322:1555.
14. Lorish, T.R. 1989. Stiff-man syndrome updated. *Mayo Clin. Proc.* 64:629.
15. Karlsen, A.E., W.A. Hagopian, J.S. Petersen, E. Boel, T. Dyrberg, C.E. Grubin, B.K. Michelsen, O.D. Madsen, and Å. Lernmark. 1992. Recombinant glutamic acid decarboxylase (representing the single isoform expressed in human islets) detects IDDM-associated 64,000-M_r autoantibodies. *Diabetes*. 41:1355.
16. Michelsen, B.K., J.S. Petersen, J.S. Boel, A. Møldrup, T. Dyrberg, and O.D. Madsen. 1991. Cloning, characterization, and autoimmune recognition of rat islet glutamic acid decarboxylase in insulin-dependent diabetes mellitus. *Proc. Natl. Acad. Sci. USA*. 88:8754.
17. Bu, D.F., M.G. Erlander, B.C. Hitz, N.J.K. Tillakaratne, D.L. Kaufman, C.B. Wagner-McPherson, G.A. Evans, and A.J. Tobin. 1992. Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene. *Proc. Natl. Acad. Sci. USA*. 89:2115.
18. Wong, G.H.W., P.F. Bartlett, I. Clark-Lewis, F. Battye, and J.W. Schrader. 1984. Inducible expression of H-2 and Ia antigens on brain cells. *Nature (Lond.)*. 310:688.
19. Baekkeskov, S., T. Kanatsuna, L. Klareskog, D.A. Nielsen, P.A. Peterson, A.H. Rubenstein, D.F. Steiner, and Å. Lernmark. 1981. Expression of major histocompatibility antigens on pancreatic islet cells. *Proc. Natl. Acad. Sci. USA*. 78:6456.
20. Oldstone, M.B., M. Nerenberg, P. Southern, J. Price, and H. Lewicki. 1991. Virus infection triggers insulin-dependent dia-

- betes mellitus in a transgenic model: role of anti-self (virus) immune response. *Cell*. 65:319.
21. Ohashi, P.S., S. Oehen, K. Buerki, H. Pircher, C.T. Ohashi, B. Odermatt, B. Malissen, R.M. Zinkernagel, and H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. *Cell*. 65:305.
 22. Richter, W., Y. Shi, and S. Baekkeskov. 1993. Autoreactive epitopes in glutamic acid decarboxylase defined by diabetes-associated human monoclonal antibodies. *Proc. Natl. Acad. Sci. USA*. 90:2832.
 23. Mauch, L., C.C. Abney, H. Berg, W.A. Scherbaum, B. Liedvogel, and W. Northemann. 1993. Characterization of a linear epitope within the human pancreatic 64-kDa glutamic acid decarboxylase and its autoimmune recognition by sera from insulin-dependent diabetes mellitus patients. *Eur. J. Biochem*. 212:597.
 24. Butler, M.H., M. Solimena, R. Dirks, Jr., A. Hayday, and P. De Camilli. 1993. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. *J. Exp. Med.* 178:2097.
 25. Christie, M., M. Landin-Olsson, G. Sundkvist, G. Dahlquist, Å. Lernmark, and S. Baekkeskov. 1988. Antibodies to a Mr-64000 islet cell protein in Swedish children with newly diagnosed Type 1 (insulin-dependent) diabetes. *Diabetologia*. 31:597.
 26. Aanstoot, H.-J., E. Sigurdsson, Y. Shi, S. Christgau, D. Grobbee, G.J. Bruining, J.L. Molenaar, A. Hofman, and S. Baekkeskov. 1994. Value of antibodies to GAD₆₅ combined with islet cell cytoplasmic antibodies for predicting type 1 (insulin dependent) diabetes mellitus in a childhood population. *Diabetologia*. In press.
 27. Kim, J., W. Richter, H.-J. Aanstoot, Y. Shi, Q. Fu, R. Rajotte, G. Warnock, and S. Baekkeskov. 1993. Differential expression of GAD₆₅ and GAD₆₇ in human, rat, and mouse pancreatic islets. *Diabetes*. 42:1799.
 28. Chang, Y.C., and D.I. Gottlieb. 1988. Characterization of the proteins purified with monoclonal antibodies to glutamic acid decarboxylase. *J. Neurosci*. 8:2123.
 29. Gottlieb, D.I., Y.C. Chang, and J.E. Schwob. 1986. Monoclonal antibodies to glutamic acid decarboxylase. *Proc. Natl. Acad. Sci. USA*. 83:8808.
 30. Summers, M.D., and G.E. Smith. 1987. A manual of methods for baculovirus vectors and insect cell culture procedures. *Tex. Agric. Exp. Stn. Bull.* 1555:1.
 31. Landin-Olsson, M., F.A. Karlsson, Å. Lernmark, G. Sundkvist, and the Diabetes Incidence Study in Sweden Group. 1992. Islet cell and thyrogastric antibodies in 633 consecutive 15- to 34-yr-old patients in the diabetes incidence study in Sweden. *Diabetes*. 41:1022.
 32. Greenbaum, C.J., J.P. Palmer, S. Nagataki, Y. Yamaguchi, J.L. Molenaar, W.A.M. Van Beers, N.K. Maclaren, and Å. Lernmark and Participating Laboratories. 1991. Improved specificity of ICA assays in the Fourth International Immunology of Diabetes Serum Exchange Workshop. *Diabetes*. 41:1570.
 33. Erlich, H.A., T. Bugawan, A. Begovich, S. Scharf, R. Griffith, R. Higuchi, and P.S. Walsh. 1991. HLA-DR, DQ, and DP typing using PCR amplification and immobilized probes. *Eur. J. Immunogenet.* 18:33.
 34. Bugawan, T., and H.A. Erlich. 1991. Rapid typing of HLA-DQB1 DNA polymorphism using nonradioactive oligonucleotide probes and amplified DNA. *Immunogenetics*. 33:163.
 35. Erlich, H.A. 1990. HLA class II polymorphism and genetic susceptibility to insulin-dependent diabetes mellitus. *Curr. Top. in Microbiol. Immunol.* 164:41.
 36. Ujihara, N., D. Daw, R. Gianani, Y. Liping, and A.C. Powers. 1993. Identification of distinct GAD autoantibody subtypes and a GAD protein epitope. *Autoimmunity*. 15(Suppl.):68.
 37. Richter, W., S. Seissler, W. Northemann, S. Wolfahrt, H.-M. Meinck, and W.A. Scherbaum. 1993. Cytoplasmic islet cell antibodies recognize distinct islet antigens in IDDM but not in stiff man syndrome. *Diabetes*. 41:1642.
 38. Moersch, F.P., and W.H. Woltman. 1956. Progressive and fluctuating muscular rigidity and spasm (stiff-man syndrome): report of a case and some observation in 13 other cases. *Mayo Clin. Proc.* 31:421.
 39. De Camilli, P., A. Thomas, R. Cofell, F. Folli, B. Lichte, G. Piccolo, H.-M. Meinck, M. Austoni, G. Fassetta, G. Bottazzo, et al. 1993. The synaptic vesicle-associated protein amphiphysin is the 138-kD autoantigen of stiff-man syndrome with breast cancer. *J. Exp. Med.* 178:2219.
 40. Nagata, M., and J.-W. Yoon. 1992. Studies on autoimmunity for T cell-mediated β -cell destruction. *Diabetes*. 41:998.
 41. Lanzavecchia, A. 1987. Antigen uptake and accumulation in antigen-specific B cells. *Immunol. Rev.* 99:39.
 42. Watts, C., and A. Lanzavecchia. 1993. Suppressive effect of antibody on processing of T cell epitopes. *J. Exp. Med.* 178:1459.
 43. Docherty, M. 1991. Novel neuronal neurotransmitter-specific cell-surface molecules. *Biochem. Soc. Trans.* 19:87.